Safety evaluation of olaparib for treating ovarian cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of brca1 and brca2 penetrance. J Clin Oncol 2007;25:1329-33
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. Brca mutation frequency and patterns of treatment response in brca mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012;30:2654-63
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):24-32
   Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, et al. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10:211-24
   PubMed Web of Science ®Google Scholar
• Friedlander ML, Stockler MR, Butow P, et al. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: Time to think differently? J Clin Oncol 2013;31:2362
   PubMed Web of Science ®Google Scholar
• Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007;64:129-38
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The icon4/ago-ovar-2.2 trial. Lancet 2003;361:2099-106
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the ago-ovar, the ncic ctg, and the eortc gcg. J Clin Oncol 2006;24:4699-707
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential. Clin Cancer Res 2013;19:961-8
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47 (Suppl 3):S16-30
   Google Scholar
• Ratner ES, Sartorelli AC, Lin ZP. Poly (adp-ribose) polymerase inhibitors: On the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012;24:564-71
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. Parp inhibition: Parp1 and beyond. Nat Rev Cancer 2010;10:293-301
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012;72:5588-99
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011;105(8):1114-22
   PubMed Web of Science ®Google Scholar
• Deeks ED. Olaparib: first global approval. Drugs 2015;75(2):231-40
   PubMed Web of Science ®Google Scholar
• Lheureux S, Oza A. Olaparib for the treatment of ovarian cancer. Expert Opin Orphan Drugs 2014;2(5):497-508
   Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Bundred N, Gardovskis J, Jaskiewicz J, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31(4):949-58
   PubMed Web of Science ®Google Scholar
• Murai J, Zhang Y, Morris J, et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 2014;349(3):408-16
   PubMed Web of Science ®Google Scholar
• Vergote I, Rutten A, Rolfo CD, et al. Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation. J Clin Oncol, 32(5s Suppl): abstract 2599
   Google Scholar
• Molife LR, Forster MD, Krebs M, et al. A phase 1 study to determine the comparative bioavailability of two different oral formulations of the parp inhibitor, olaparib (azd2281), in patients with advanced solid tumors. ASCO Meeting Abstracts 2010;28:2599
   Google Scholar
• Gupta A, Moreno V, Dean EJ, et al. Phase 1 study to determine the bioavailability and tolerability of a tablet formulation of the parp inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase. ASCO Meeting Abstracts 2012;30:3051
   Google Scholar
• Molife LR, Mateo J, McGoldrick T, et al. Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. ASCO Meeting Abstracts 2012;30:3048
   Google Scholar
• Mateo J, Friedlander M, Sessa C, et al. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline brca1/2 mutation to determine an optimal dosing schedule for the tablet formulation [abstract 801]. The European Journal of Cancer 2013;49(9):S161
   Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with brca1 or brca2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010;376:245-51
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase 2, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (adp-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with brca1 or brca2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372-9
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: A randomized phase 3 study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22
   PubMed Web of Science ®Google Scholar
• Adams SF, Marsh EB, Elmasri W, et al. A high response rate to liposomal doxorubicin is seen among women with brca mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 2011;123:486-91
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244-50
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852-61
   PubMed Web of Science ®Google Scholar
• Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015;16(1):87-97
   PubMed Web of Science ®Google Scholar
• AstraZenecaAB. Lynparza 50 mg hard capsules: EU summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/ema
   Google Scholar
• AstraZeneca Global. Lynparza approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer [media release]. 2014. Available from: http://astrazeneca.com
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) capsules, for oral use: US prescribing information. 2014. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfada/index.cfm
   Google Scholar
• US FDA. FDA approves Lynparza to treat advanced ovarian cancer [media release]. 2014. Available from: http://www.fda.gov/newsevents/newsroom/pressannoucements/ucm427554.htm
   Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Health-related quality of life (HRQoL) during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) and a BRCA mutation (BRCAm). Ann Oncol 2014;25:Suppl_4
   Google Scholar
• Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(adp-ribose) polymerase (parp) inhibitor, olaparib (azd2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase 1 study. Invest New Drugs 2012;30:1493-500
   PubMed Web of Science ®Google Scholar
• Khan OA, Gore M, Lorigan P, et al. A phase 1 study of the safety and tolerability of olaparib (azd2281, ku0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011;104:750-5
   PubMed Web of Science ®Google Scholar
• Dent RA, Lindeman GJ, Clemons M, et al. Phase 1 trial of the oral parp inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88
   PubMed Web of Science ®Google Scholar
• Lee J, Annunziata CM, Minasian LM, et al. Phase 1 study of the parp inhibitor olaparib (o) in combination with carboplatin (c) in brca1/2 mutation carriers with breast (br) or ovarian (ov) cancer (ca). ASCO Meeting Abstracts 2011;29:2520
   Google Scholar
• Rajan A, Carter CA, Kelly RJ, et al. A phase 1 combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:2344-51
   PubMed Web of Science ®Google Scholar
• van der Noll R, Ang JE, Jager A, et al. Phase 1 study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. ASCO Meeting Abstracts 2013;31:2579
   Google Scholar
• Dean E, Middleton MR, Pwint T, et al. Phase 1 study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012;106:468-74
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study. Lancet Oncol 2014;15(11):1207-14
   PubMed Web of Science ®Google Scholar
• Del Conte G, Sessa C, von Moos R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 2014;111(4):651-9
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Nokihara H, Yamada Y, et al. A phase 1, dose-finding and pharmacokinetic study of olaparib (azd2281) in Japanese patients with advanced solid tumors. Cancer Sci 2012;103:504-9
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill M, Aghajanian C, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—a Gynecologic Oncology Group study. Gynecol Oncol 2014;133:56-7
   PubMedGoogle Scholar
• Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014;133(2):362-9
   Google Scholar
• Walsh CS. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol 2015; pii: S0090-8258(15)00657 -5; In press
   Web of Science ®Google Scholar
• Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013;40(6):666-75
   PubMed Web of Science ®Google Scholar
• Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340(5):351-7
   PubMed Web of Science ®Google Scholar